Janux appoints Winston Kung to board; Stefan Heller resigns

Janux Therapeutics, Inc.

Winston Kung appointed as Class I director, term expiring at 2025 annual meeting, effective Sept 21, 2022.
Stefan Heller resigned from board effective same day; not due to any disagreement with the company.
Kung receives $40k annual cash retainer (board) + $4k (committee) and stock options: 30k shares (3-yr vest) and 9,375 shares (1-yr vest).
Kung is CFO/COO at PMV Pharma; prior VP Business Development at Celgene and roles at Citigroup and Amgen.
Changes effective immediately per press release dated September 22, 2022.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stefan Heller

Director

JANX · Janux Therapeutics, Inc.

Effective: 2022-09-21
Filed: September 22, 2022, 7:59 PM ET

Also on September 21, 2022, Stefan Heller, Ph.D., resigned as a member of the Board effective as of such date.

Appointed

Winston Kung

Class I director

JANX · Janux Therapeutics, Inc.

Effective: 2022-09-21
Filed: September 22, 2022, 7:59 PM ET

On September 21, 2022, the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), appointed Winston Kung as a Class I director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stefan Heller resigned as Director at Janux Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Also on September 21, 2022, Stefan Heller, Ph.D., resigned as a member of the Board effective as of such date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Winston Kung was appointed as Class I director at Janux Therapeutics, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

On September 21, 2022, the Board of Directors (the “Board”) of Janux Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Governance Committee”), appointed Winston Kung as a Class I director of the Company

View on SEC.gov

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-018774

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.